Remternetug

Ascension Alexian Brothers hospital is conducting trials for remternetug, a new subcutaneous Alzheimer's treatment derived from donanemab that patients can self-administer at home.

Washington University School of Medicine initiates a pioneering trial of remternetug, a monoclonal antibody designed to prevent Alzheimer's disease by targeting amyloid-beta before symptom onset.

WashU Medicine initiates groundbreaking international trial testing Eli Lilly's remternetug in young adults as young as 18, targeting Alzheimer's prevention up to 25 years before expected symptom onset.

The global Alzheimer's disease market is projected to grow at a CAGR of 23.4%, expanding from $2.4B in 2023 to $19.3B by 2033 across eight major markets.

Eli Lilly's Kisunla (donanemab-azbt) has been approved in China for treating early symptomatic Alzheimer's disease in adults, marking its fourth major market approval.